BioSpace News Archive

XORTX Therapeutics Inc. announces that it is exploring the potential of using XRx-101 (a new formulation of Oxypurinol) as a novel treatment for acute kidney and lung

Blueprint Medicines Corporation today announced updated results from the Phase 2 pioneer trial.

BioNTech SE provides further details on the Company’s R&D effort, “Project Lightspeed”, to develop a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease.

Lysogene announced the amendment of its corporate agenda* for 2020.

Medivir AB announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir’s preclinical research programs.

Kodiak Sciences Inc. today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019 .

March 16, 2020 10:00 UTC Axonics ® Announces Filing of Petitions Before the United States Patent and Trademark Office Contesting the Validity of Medtronic Patents

TherapeuticsMD, Inc. , today provided an update on its business operations as the COVID-19 situation evolves. At this time, TherapeuticsMD continues to provide an uninterrupted supply of its portfolio of products for patients. The company has activated virtual options to ensure business continuity

Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax’’ or the ''Company’’), an outcome-driven connected healthcare company, today announced it has received preliminary approval for registration into the U.S. Government’s System for Award Management, (“SAM”) as part of the Company’s efforts to work with the Center for Disease Control and Prevention, (“CDC”) in Atlanta, Georgia